Restricted accessResearch articleFirst published online 2017-08
Program Implementation of Option B+ at a President's Emergency Plan for AIDS Relief-Supported HIV Clinic Improves Clinical Indicators But Not Retention in Care in Mbarara,Uganda
2013 WHO guidelines for prevention of mother to child transmission recommend combination antiretroviral therapy (ART) for all pregnant women, regardless of CD4 count (Option B/B+). We conducted a retrospective analysis of data from a government-operated HIV clinic in Mbarara, Uganda before and after implementation of Option B+ to assess the impact on retention in care. We limited our analysis to women not on ART at the time of their first reported pregnancy with CD4 count >350. We fit regression models to estimate relationships between calendar period (Option A vs. Option B+) and the primary outcome of interest, retention in care. One thousand and sixty-two women were included in the analysis. Women were more likely to start ART within 6 months of pregnancy in the Option B+ period (68% vs. 7%, p < 0.0001) and had significantly greater increases in CD4 count 1 year after pregnancy (+172 vs. −5 cells, p < 0.001). However, there was no difference in the proportion of women retained in care 1 year after pregnancy (73% vs. 70%, p = 0.34). In models adjusted for age, distance to clinic, marital status, and CD4 count, Option B+ was associated with a nonsignificant 30% increased odds of retention in care at 1 year [adjusted odds ratio (AOR) = 1.30, 95% CI 0.98–1.73, p = 0.06]. After transition to an Option B+ program, pregnant women with CD4 count >350 were more likely to initiate combination therapy; however, interventions to mitigate losses from HIV care during pregnancy are needed to improve the health of women, children, and families.
Get full access to this article
View all access options for this article.
References
1.
World Health Organization. PMTCT strategic vision 2010–2015: Preventing mother-to-child transmission of HIV to reach the UNGASS and Millennium Development Goals: Moving towards the elimination of paediatric HIV, 2010.
2.
PEPFAR. Guidance on integrating prevention of mother to child transmission of HIV, maternal, neonatal, and child health and pediatric HIV services, 2011.
3.
NewellML. Prevention of mother-to-child transmission of HIV: Challenges for the current decade. Bull World Health Organ, 2001; 79:1138–1144.
4.
UNAIDS. Joint United Nations Programme on HIV/AIDS “The Gap Report”, 2014.
5.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Summary of key features and recommendations, 2013.
6.
FowlerMG, QinM, FiscusSA, et al.Benefits and risks of antiretroviral therapy for perinatal HIV prevention. New Engl J Med, 2016; 375:1726–1737.
7.
CurrierJS, BrittoP, HoffmanRM, et al.Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3 (PROMISE 1077HS). Paper presented at: 21st International AIDS Conference (AIDS 2016). July 2016; Durban, South Africa. Abstract 10082.
8.
Centers for Disease Control and Prevention (CDC). Impact of an innovative approach to prevent mother-to-child transmission of HIV—Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep, 2013; 62:148–151.
9.
GuptaS, JahnA, BarrB. Malawi's Option B+ 2011–2015: The Impact of Rapid ART Decentralization. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI). February 2016, Boston, Abstract 789.
10.
TenthaniL, HaasAD, TweyaH, et al.Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women (‘Option B+’) in Malawi. AIDS, 2014; 28:589–598.
11.
KimMH, AhmedS, HosseinipourMC, et al.Implementation and operational research: The impact of option B+ on the antenatal PMTCT cascade in Lilongwe, Malawi. J Acq Immune Defic Syndr, 2015; 68:e77–e83.
12.
ClouseK, PettiforA, ShearerK, et al.Loss to follow-up before and after delivery among women testing HIV positive during pregnancy in Johannesburg, South Africa. Trop Med Int Health, 2013; 18:451–460.
13.
NachegaJB, UthmanOA, AndersonJ, et al.Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: A systematic review and meta-analysis. AIDS, 2012; 26:2039–2052.
14.
UNAIDS. The HIV and AIDS Uganda Country Progress Report, 2014.
15.
UNAIDS. Uganda HIV Epidemic Profile, 2014.
16.
KamuyangoAA, HirschhornLR, WangW, JansenP, HoffmanRM. One-year outcomes of women started on antiretroviral therapy during pregnancy before and after the implementation of Option B+ in Malawi: A retrospective chart review. World J AIDS, 2014; 4:332–337.
17.
HerlihyJM, HamombaL, BonawitzR, et al.Implementation and operational research: Integration of PMTCT and antenatal services improves combination antiretroviral therapy uptake for HIV-positive pregnant women in Southern Zambia: A prototype for Option B+?. J Acquir Immune Defic Syndr, 2015; 70:e123–e129.
18.
AhmedS, KimMH, AbramsEJ. Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women: A review of the evidence for the Option B+ approach. Curr Opin HIV AIDS, 2013; 8:474–489.
19.
SiednerMJ, NgCK, BassettIV, KatzIT, BangsbergDR, TsaiAC. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002–2013: A meta-analysis. Clin Infect Dis, 2015; 60:1120–1127.
20.
Dryden-PetersonS, LockmanS, ZashR, et al.Initial programmatic implementation of WHO option B in Botswana associated with increased projected MTCT. J Acquir Immune Defic Syndr, 2015; 68:245–249.
21.
IroeziND, MindryD, KawaleP, ChikowiG, JansenPA, HoffmanRM. A qualitative analysis of the barriers and facilitators to receiving care in a prevention of mother-to-child program in Nkhoma, Malawi. Afr J Reprod Health, 2013; 17(4 Spec No):118–129.
22.
BwirireLD, FitzgeraldM, ZachariahR, et al.Reasons for loss to follow-up among mothers registered in a prevention-of-mother-to-child transmission program in rural Malawi. Trans R Soc Trop Med Hyg, 2008; 102:1195–1200.
23.
KaidaA, MatthewsLT, AshabaS, et al.Depression during pregnancy and the postpartum among HIV-infected women on antiretroviral therapy in Uganda. J Acquir Immune Def Syndr, 2014; 67Suppl 4:S179–S187.
24.
MatthewsLT, AshabaS, PsarosC, et al.From Option A to Option B+: Exploring challenges of navigating evolving PMTCT strategies among postpartum women living with HIV in rural Uganda. Paper presented at: International AIDS Society (AIS). July 2015; Vancouver. Abstract MOPEB188.
25.
MatthewsLT, RibaudoHB, KaidaA, et al.HIV-infected Ugandan women on antiretroviral therapy maintain HIV-1 RNA suppression across periconception, pregnancy, and postpartum periods. J Acquir Immune Def Syndr, 2016; 71:399–406.
26.
SchnackA, RempisE, DeckerS, et al.Prevention of mother-to-child transmission of HIV in option B+ era: Uptake and adherence during pregnancy in Western Uganda. AIDS Patient Care STDs, 2016; 30:110–118.
27.
KossC, NatureebaP, HavlirD. Viral suppression and retention 2–5 years after ART initiation in pregnancy in Uganda. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI). February 2016; Boston. Abstract 768.
28.
FayorseyR, ChegeD, WangC, et al.Randomized trial of a lay counselor-led combination intervention for PMTCT retention. Paper presented at: Conference on Retroviruses and Opportunistic Infections. February 2016; Boston. Abstract 791.
29.
AliyuM, BlevinsM, AudetC, et al.. Optimizing PMTCT outcomes in rural North-Central Nigeria: A cluster-randomized study. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI). February 2016; Boston. Abstract 790.
30.
YotebiengM, ThirumurthyH, MoraccoKE, et al.Conditional cash transfers to increase retention in PMTCT care, antiretroviral adherence, and postpartum virological suppression: A randomized controlled trial. J Acquir Immune Def Syndr, 2016; 72Suppl 2:S124–S129.
31.
GimbelS, RustagiAS, RobinsonJ, et al.Evaluation of a systems analysis and improvement approach to optimize prevention of mother-to-child transmission of HIV using the consolidated framework for implementation research. J Acquir Immune Def Syndr, 2016; 72Suppl 2:S108–S116.
32.
RustagiAS, GimbelS, NduatiR, et al.Implementation and operational research: Impact of a systems engineering intervention on PMTCT service delivery in Cote d'Ivoire, Kenya, Mozambique: A cluster randomized trial. J Acquir Immune Def Syndr, 2016; 72:e68–e76.
33.
AaronsGA, SommerfeldDH, ChiBH, et al.Concept mapping of PMTCT implementation challenges and solutions across 6 sub-Saharan African Countries in the NIH-PEPFAR PMTCT implementation science alliance. J Acquir Immune Def Syndr, 2016; 72Suppl 2:S202–S206.
34.
EzeanolueEE, PowellBJ, PatelD, et al.Identifying and prioritizing implementation barriers, gaps, and strategies through the Nigeria implementation science alliance: Getting to zero in the prevention of mother-to-child transmission of HIV. J Acquir Immune Def Syndr, 2016; 72Suppl 2:S161–S166.
35.
SturkeR, SiberryG, MofensonL, et al.Creating sustainable collaborations for implementation science: The case of the NIH-PEPFAR PMTCT implementation science alliance. J Acquir Immune Def Syndr, 2016; 72Suppl 2:S102–S107.
36.
ClouseK, VermundS, FoxMP. Continuity of care among pregnant women lost to follow-up after initiating ART. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI). February 2016; Boston. Abstract 792.
